Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05050669 · ClinicalTrials.gov registry record
Natural History Study of ENPP1 Deficiency and the Early-onset Form of ABCC6 Deficiency
A clinical trial, sponsored by Inozyme Pharma.
- Completed
- Registry status
- 12
- Enrollment target
NCT05050669: Completed study, sponsored by Inozyme Pharma.
NCT05050669 is a clinical trial that has completed, run by Inozyme Pharma. The registered enrollment target is 12 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05050669 has completed, sponsored by Inozyme Pharma.
- COMPLETED
- Registry status
- 12 participants
- Enrollment target
Study Summary
The purpose of this prospective study is to characterize the natural history of ENPP1 Deficiency and the early-onset form of ABCC6 Deficiency longitudinally. The study will prospectively gather information about the biochemical, physiological, anatomic, radiographic, and functional manifestations (including patient reported outcomes) of each disease.
Primary Outcome
For each subject, blood plasma will be assayed for Plasma Inorganic Pyrophosphate (PPi), comparing the subjects baseline value over time
Interventions
- OTHER No Intervention for this observational study
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2022-06-28 |
| Est. Completion | 2024-06-26 |
What the finished NCT05050669 record still lists
NCT05050669 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 12 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which No Intervention for this observational study is the first listed.
NCT05050669 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05050669 about?
NCT05050669 is a clinical study titled "Natural History Study of ENPP1 Deficiency and the Early-onset Form of ABCC6 Deficiency". The purpose of this prospective study is to characterize the natural history of ENPP1 Deficiency and the early-onset form of ABCC6 Deficiency longitudinally. The study will prospectively gather information about the biochemical, physiological, anatomic, radiographic, and functional manifestations (i...
What is the current status of trial NCT05050669?
This trial is currently completed. The enrollment target is 12 participants. The study started on 2022-06-28. Estimated completion is 2024-06-26.
What interventions are being tested in trial NCT05050669?
The interventions under investigation include: No Intervention for this observational study (OTHER).
Who is sponsoring clinical trial NCT05050669?
This trial is sponsored by Inozyme Pharma, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI